Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LianBioLIAN · Entity 9881 | Director · Chief Executive Officer | March 29, 2023 | March 31, 2023 |
| Zai Lab LtdZLAB · Entity 4271 | Operating Partner | May 11, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LianBio
Report date March 29, 2023 · Filed March 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 907,498 |
Reported balance
After 2023-03-29 transaction · row 1
1 source rowRow 1 · 2023-03-29 · Grant · Acquired 907,498 · Balance 907,498 F1: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date.
Zai Lab Ltd
Report date May 11, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.32 · Expires 2036-05-11 | Direct | 136,819 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 136,819 · Balance 136,819 F2: The option vests in equal annual installments over four years beginning on 05/11/2027, the first anniversary of the date of grant, subject to continuous service. F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 59,288 |
Reported balance
After 2026-05-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-11 · Grant · Acquired 59,288 · Balance 59,288 F3: Each Restricted Share Unit ("RSU") represents a contingent right to receive one ADS. F4: The RSUs vest in equal annual installments over four years beginning on 05/11/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2: The option vests in equal annual installments over four years beginning on 05/11/2027, the first anniversary of the date of grant, subject to continuous service.
F3: Each Restricted Share Unit ("RSU") represents a contingent right to receive one ADS.
F4: The RSUs vest in equal annual installments over four years beginning on 05/11/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2026 Filed Jun 8, 2026 20:29 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantRestricted Share Units · Derivative | 59,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002826 · form4.xml · derivative · entry 2 Wang Yizhe · CIK 0001884248 · Operating Partner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,288 Underlying: American Depositary Shares · 59,288 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Share Unit ("RSU") represents a contingent right to receive one ADS. F4 · derivative.exercise_date: The RSUs vest in equal annual installments over four years beginning on 05/11/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F4 · derivative.expiration_date: The RSUs vest in equal annual installments over four years beginning on 05/11/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. Read SEC document |
| May 11, 2026 Filed Jun 8, 2026 20:29 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantStock Option (Right to Buy) · Derivative | 136,819 | $0.00 Strike: $20.32 | $0.00 |
DisclosureSEC source: 0000905148-26-002826 · form4.xml · derivative · entry 1 Wang Yizhe · CIK 0001884248 · Operating Partner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,819 Underlying: American Depositary Shares · 136,819 shares Expires 2036-05-11 F2 · derivative.exercise_date: The option vests in equal annual installments over four years beginning on 05/11/2027, the first anniversary of the date of grant, subject to continuous service. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:18 UTC | LianBio LIAN · Entity 9881 | GrantOrdinary Shares | 907,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001831283-23-000052 · wf-form4_168029388148981.xml · nonDerivative · entry 1 Wang Yizhe · CIK 0001884248 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 907,498 F1 · shares: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on March 29, 2024; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on March 29, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:08 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 1,292,324 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001831283-23-000015 · wf-form4_167459451349704.xml · derivative · entry 1 Wang Yizhe · CIK 0001884248 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,292,324 Underlying: Ordinary Shares · 1,292,324 shares Expires 2033-01-20 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest and become exercisable on January 20, 2024; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 20, 2027, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.